Estrogen Hormone Protocol
Launched by NATIONAL INSTITUTE ON AGING (NIA) · Oct 29, 1999
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen replacement therapy, who have had a hysterectomy, and who are in stable general health.
- Exclusion Criteria:
- • Patients with an uncontrolled health problem, such as untreated high blood pressure or thyroid disease.
About National Institute On Aging (Nia)
The National Institute on Aging (NIA) is a prominent research organization within the National Institutes of Health (NIH) dedicated to advancing our understanding of aging and age-related diseases. Through a robust portfolio of clinical trials, the NIA focuses on innovative research that aims to enhance the health and well-being of older adults. By fostering collaboration among scientists, healthcare professionals, and communities, the NIA seeks to translate research findings into practical solutions that improve the quality of life for aging populations. Their commitment to rigorous scientific inquiry and public health underscores their role as a leader in geriatric research and the pursuit of effective interventions for age-associated conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Baltimore, Maryland, United States
Houston, Texas, United States
Tampa, Florida, United States
Jacksonville, Florida, United States
Atlanta, Georgia, United States
Springfield, Illinois, United States
Kansas City, Kansas, United States
Lexington, Kentucky, United States
Minneapolis, Minnesota, United States
St. Louis, Missouri, United States
New York, New York, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
Seattle, Washington, United States
Birmingham, Alabama, United States
San Diego, California, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
White Plains, New York, United States
Indianapolis, Indiana, United States
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Leon Thal, MD.
Principal Investigator
University of California, San Diego
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials